HST Medical, a Singapore-based provider of premium health supplements and wellness products, has been acquired by Kowa Pharmaceutical Asia Pte. Ltd., a sub-subsidiary of Japan's Kowa Company, Ltd., effective May 29, 2026.

Following the acquisition, HST Medical will operate as a wholly owned subsidiary of Kowa Pharmaceutical Asia. 

The company said the transaction marks a significant milestone in its growth strategy, enabling the expansion of its Singapore-born health and wellness brands into international markets while retaining its local identity and leadership.

Known for its flagship Rheuma-Salve pain relief balm and a portfolio of science-backed wellness products, HST Medical plans to leverage Kowa's global capabilities to accelerate international expansion.

The acquisition will provide HST Medical with access to Kowa's established export network across ASEAN and other global markets. 

Products including the Rheuma-Salve, Heritage, HST Medical and Zoo-Vite ranges are expected to be introduced into new international markets where the Kowa Group already has a commercial presence.

The partnership will also strengthen product development capabilities, with Kowa supporting the modernization and expansion of HST Medical's product portfolio.

HST Medical said its brand identity and local leadership will remain unchanged following the acquisition. 

Ellis Tanwill continue as General Manager, while co-founder Simone Tan will serve as Director and Head of Business Development, supporting the integration process and leading the company's international expansion initiatives alongside President Nikhil Kapur.

Nikhil Kapur, President of HST Medical, said, "By aligning HST Medical's rich heritage of trust and consumer-focused innovation with Kowa's global infrastructure and pharmaceutical expertise, we are not only scaling our reach but also ensuring that our science-backed wellness solutions can positively impact more lives internationally.”